Form 4: Akebia Therapeutics Executive Richard C. Malabre Reports Stock Transactions
SEC Form 4 Filing
Richard C. Malabre, SVP and Chief Accounting Officer of Akebia Therapeutics, reports acquisition and disposal of company stock and stock options.
Summary
- Richard C. Malabre, SVP, Chief Accounting Officer of Akebia Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On January 31, 2025, Malabre acquired 85,000 shares of common stock through restricted stock units and was granted options to buy 128,000 shares.
- On February 3, 2025, Malabre sold 30,202 shares of common stock at $2.1 per share to cover tax withholding obligations related to vesting restricted stock units.
- Following these transactions, Malabre directly owns 280,248 shares of Akebia Therapeutics common stock and options to buy 128,000 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and expected as part of executive compensation. The sale of shares is for tax obligations, which is a common practice.
Positives
- The grant of restricted stock units and stock options to a key executive signals confidence in the company's future performance.
Negatives
- The sale of shares by the executive, even for tax obligations, could be perceived negatively by some investors.
Risks
- Executive stock sales, even if planned, can sometimes create short-term price volatility.
Future Outlook
The restricted stock units vest over three years, and the options vest over four years, contingent on continued service with the company.
Industry Context
Executive stock transactions are common and closely watched in the biotech industry as indicators of management's confidence in the company's prospects.
Comparison to Industry Standards
- Stock option grants and restricted stock units are standard compensation practices in the biotechnology industry, used to align executive incentives with shareholder value.
- The vesting schedules described are typical for such grants, encouraging long-term commitment from the executive.
- Rule 10b5-1 trading plans are frequently used by corporate insiders to manage sales of company stock and avoid accusations of insider trading; many companies such as Amgen, Gilead, and Biogen have executives that use these plans.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the potential for short-term price fluctuations.
Key Dates
| Date | Description |
|---|---|
| December 23, 2023 | Reporting person adopted a Rule 10b5-1 trading plan |
| December 31, 2024 | Purchase of 1,500 shares of the Issuer's common stock under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. |
| January 31, 2024 | Grant date for restricted stock units, one-third of which vested on January 31, 2025. |
| January 31, 2025 | Grant date of restricted stock units and stock options. |
| January 31, 2035 | Expiration date of stock options. |
| February 03, 2025 | Sale of 30,202 shares of common stock. |
| February 04, 2025 | Date of Form 4 filing. |
Keywords
Form 4, Akebia Therapeutics, AKBA, Richard C. Malabre, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.